Treatment of cancers expressing p95 ErbB2

Details Treatment of cancers expressing p95 ErbB2 Treatment of cancers expressing p95 ErbB2

2009-02-05

2010-11-09

Harris, Alana M (Department: 1643)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S004000, C514S002600, C530S300000, C530S350000

Reexamination Certificate

active

07829297

ABSTRACT:
The truncated ErbB2 receptor (p95ErbB2) is shown to differ from the full-length ErbB2 receptor in its association with other ErbB receptors. The truncated receptor preferentially associated with ErbB3, whereas full length ErbB2 heterodimerizes with either EGFR or ErbB3. Consistent with p95ErbB2heterodimerization with ErbB3, it is shown that heregulin (an ErbB3 ligand) stimulates p95ErbB2phosphorylation in breast cancer cell lines. Described herein are methods of identifying patients suitable for treatment with a p95ErbB2inhibitor, and methods of treating such patients.

REFERENCES:
patent: 6169091 (2001-01-01), Cockerill et al.
patent: 6174889 (2001-01-01), Cockerill et al.
patent: 6207669 (2001-03-01), Cockerill et al.
patent: 6391874 (2002-05-01), Cockerill et al.
patent: 6541214 (2003-04-01), Clinton
patent: 2003/0219842 (2003-11-01), Carney et al.
patent: 2005/0272120 (2005-12-01), Dowd et al.
patent: 2006/0094068 (2006-05-01), Bacus et al.
patent: 9935146 (1999-07-01), None
patent: 0104111 (2001-01-01), None
patent: 0202552 (2002-01-01), None
patent: 02056912 (2002-07-01), None
patent: 03086467 (2003-10-01), None
Chen et al.; “Strategies to Target HER2
eu Overexpression for Cancer Therapy”; Drug Resistance Updates; 2003; vol. 6, No. 3; pp. 129-136.
Molina et al.; “NH(2)-Terminal Truncated HER-2 Protein but not Full Length Receptor is Associated with Nodal Metastasis in Human Breast Cancer”; Clinical Cancer Research; 2002; vol. 8, No. 2; pp. 347-353.
Zhou et al.; “Effects of the EGFR/HER2 Kinase Inhibitor GW572016 on EGFR- and HER2-Overexpressing Breast Cancer Cell Line Proliferation, Radiosensitization and Resistance”; International Journal of Radiation: Oncology Biology Physics; 2004; vol. 58, No. 2; pp. 344-352.
Xia et al.; “Truncated ErbB2 Receptor (p95 ErbB2) is Regulated by Heregulin through Heterodimer Formation with ErbB3 Yet Remains Sensitive to the Dual EGFR/ErbB2 Kinase Inhibitor GW572016”; Oncogene; 2004; vol. 23, No. 3; pp. 646-653.
Harris et al.; “Comparison of Methods of Measuring HER-2 in Metastatic Breast Cancer Patients Treated with High-Dose Chemotherapy”; Journal of Clinical Oncology; 2001; vol. 19, No. 6; pp. 1698-1706.
Difiore et al.; “erbB2 is a Potent Oncogene when Overexpressed in NIH/3T3 Cells”; Science; 1987; vol. 237; pp. 178-182.
Rusnak et al.; “The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-Derived Cell Lines in vitro and in vivo”; Molecular Cancer Therapeutics; 2001; vol. 1, No. 2; pp. 85-94.
Baselga et al.; “Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185(HER2) Monoclonal Antibody in Patients with HER2
eu-Overexpressing Metastatic Breast Cancer”; Journal of Clinical Oncology; 1996; vol. 14, No. 3; pp. 737-744.
Rusnak et al.; “The Characterization of Novel, Dual ErbB-2/EGFR, Tyrosine Kinase Inhibitors: Potential Therapy for Cancer”; Cancer Research; 2001; vol. 61, No. 19; pp. 7196-7203.
Colomer et al.; “Circulating HER2 Extracellular Domain and Resistance to Chemotherapy in Advanced Breast Cancer”; Clinical Cancer Research; 2000; vol. 6, No. 6; pp. 2356-2362.
Burris; “Dual Kinase Inhibition in the Treatment of Breast Cancer: Initial Experience with the EGFR/erbB-2 Inihbitor Lapatinib”; The Oncologist; 2004; vol. 9, Suppl. 3; pp. 10-15.
Molina et al.; “Trastuzumab (Herceptin), a Humanized Anti-HER2 Receptor Monoclonal Antibody, Inhibits Basal and Activated HER2 Ectodomain Cleavage in Breast Cancer Cells”; Cancer Research; 2001; vol. 61, No. 12; pp. 4744-4749.
Bargmann et al.; “Oncogenic activiation of the neu-encoded receptor protein by point mutation and deletion”; The EMBO Journal; 1988; vol. 7, No. 7; pp. 2043-2052.
Segatto et al.; “Different Structural Alterations Upregulate in vitro Tyrosine Kinase Activity and Transforming Potency of the erbB-2 Gene”; Molecular and Cellular Biology; 1988; vol. 8, No. 12; pp. 5570-5574.
Christianson et al.; “NH2-Terminally Truncated HER-2
eu Protein: Relationship with Shedding of the Extracellular Domain and with Prognostic Factors in Breast Cancer”; Cancer Research; 1998; vol. 58, No. 22; pp. 5123-5129.
Xia et al.; “Anti-Tumor Activity of GW572016: a Dual Tyrosine Kinase Inhibitor Blocks EGF Activation of EGFR/erbB2 and Downstream Erk1/2 and AKT Pathways”; Oncogene; 2002; vol. 21, No. 41; pp. 6255-6263.

Affiliated with

Also associated with

Rating

Treatment of cancers expressing p95 ErbB2 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of cancers expressing p95 ErbB2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of cancers expressing p95 ErbB2 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4169930